The S&P 500 has been off to its worst start in decades. Down around 20% since the beginning of the year, there's still no telling how much lower it could go or if a recovery is due to happen. With inflation still out of control, it's hard to be too optimistic things will get better for stocks, simply because the economy is still facing some significant challenges ahead.
And that's the situation I see for both Novavax (NASDAQ: NVAX) and Starbucks (NASDAQ: SBUX) . These stocks have performed even worse than the markets, with the healthcare stock falling more than 60% in 2022 and the coffee giant down by a more modest 30%. However, both look destined to fall even more before the year is over, and here's why.
Last week, Novavax finally received news from the Food and Drug Administration that its COVID-19 vaccine obtained Emergency Use Authorization for people who are 18 years of age and older. It took months of waiting before Novavax's authorization came in. And when it did, there wasn't a bang but a whimper as the stock still crashed on the news .
For further details see:
2 Struggling Stocks That Could Fall Even Further in the Second Half